Global Drug Screening Market Outlook, 2031
The Global Drug Screening Market is segmented By Product and Service (Consumables, Analytical Instruments, Rapid Testing Devices, Drug Screening Service); By Sample Type (Urine Samples, Breath Samples, Hair Samples, Oral Fluid Samples, Other Samples); By End User (Drug Testing Laboratories, Hospitals & Clinics, Others)
- Bonafide Research
- 22-01-2026
- Pages : 181
- Figures : 36
- Tables : 86
- Region : Global
- Category : Lifescience
- Medical Devices
The global drug screening market was valued at over USD 10.06 Billion in 2025 and is projected to reach USD 18.87 Billion by 2031 (CAGR 11.33%).
- Historical Period2020-2024
- Base Year2025
- Forecast Period2026-2031
- Market Size (2025) USD 10.06 Billion
- Market Size (2031) USD 18.87 Billion
- CAGR (2026-2031) 11.33%
- Largest MarketNorth America
- Fastest Market Asia-Pacific
- Format
Featured Companies
- 1. Abbott Laboratories
- 2. Drägerwerk AG & Co. KGaA
- 3. Siemens Healthineers
- 4. Shimadzu Corporation
- 5. OraSure Technologies
- 6. Quest Diagnostics
- 7. Lifeloc Technologies, Inc
- 8. Bio-Rad Laboratories, Inc.
- 9. Psychemedics Corporation
- More...
Drug Screening Market Analysis
The global drug screening market is experiencing steady growth driven by rising substance abuse worldwide, increasingly stringent regulations, expanding government funding, and continuous technological advancements that improve the accuracy and efficiency of drug testing solutions. The growing number of individuals engaging in drug use globally is directly contributing to the increased demand for screening products and services, driving innovation and advancements in the industry to cater to the rising need for effective screening solutions. Furthermore, developing improved screening technology and increasing awareness of the benefits of illicit substance screening are creating business opportunities. Moreover, the increased alcohol consumption among adolescents and the elderly is likely to fuel the demand for testing kits. The advent of workspace-based regulatory steps is expected to create opportunities for the market players, further contributing to the market's expansion. The regulatory body's approval of the new drug test also contributes to the industry expansion. For instance, in October 2023, the FDA's approval of the Alltest Fentanyl Urine Test Cassette, a rapid test for detecting fentanyl in urine, contributed to the expansion of the industry. This development provides a new tool for the preliminary detection of fentanyl, a significant driver in market's growth. The test's ability to detect fentanyl in urine samples helps in addressing the opioid crisis by enabling early detection and intervention. This innovation is expected to drive the demand for products and services, particularly in the context of opioid abuse and misuse. According to the research report "Global Drug Screening Market Outlook, 2031," published by Bonafide Research, the Global Drug Screening market was valued at more than USD 10.06 Billion in 2025, and expected to reach a market size of more than USD 18.87 Billion by 2031 with the CAGR of 11.33% from 2026-2031.The degree of innovation is high in market, particularly in developing sensitive lab-based testing methods and wearable devices for real-time drug use and metabolites monitoring. Saliva-based testing, known for its non-invasiveness and quick results, is developing testing, promising increased accessibility and accuracy. Several players engage in mergers and acquisitions to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve competency. For instance, in April 2022, Saladax Biomedical acquired portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV, expanding its intellectual property to cover major antipsychotic drugs. This acquisition enables Saladax to develop tests for hospitals and point-of-care settings. The development of innovative testing techniques such as rapid screening devices, advanced laboratory-based tests, and point-of-care testing solutions is enhancing drug screening procedures' efficiency, accuracy, and speed. Additionally, advancements in data analytics and artificial intelligence are facilitating the interpretation of test results, further driving market growth. The global drug screening market is highly competitive, characterized by a fragmented landscape with numerous global and regional players. Leading companies, such as Abbott, Quest Diagnostics, and Thermo Fisher Scientific, dominate through extensive product portfolios and advanced testing technologies. Regional players, such as Alfa Scientific Designs, focus on localized offerings, particularly in rapid testing devices. Companies are investing in innovative technologies, such as AI-driven analytics and portable testing kits, to enhance market share, driven by demand in workplace and healthcare applications.
to Download this information in a PDF
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamic
Market Drivers • Workplace Safety Regulations: A primary driver of the global drug screening market is the growing prevalence of substance abuse worldwide, including opioids, stimulants, cannabinoids, and prescription medication misuse. This trend has prompted governments, healthcare providers, and employers to implement comprehensive drug testing programs to mitigate health risks, reduce workplace accidents, and maintain public safety. Industries such as transportation, aviation, oil and gas, and healthcare have strict safety regulations that mandate pre-employment, random, and post-incident drug testing. In addition, awareness campaigns and public health initiatives encourage early detection and intervention, which further fuels demand for both point-of-care and laboratory-based drug screening solutions. • Technological Advancements: Technological innovations are driving significant growth in the drug screening market by enhancing accuracy, speed, and convenience of testing solutions. Advanced analytical techniques such as chromatography, mass spectrometry, immunoassays, and AI-enabled digital reporting systems have improved detection capabilities for a wide range of substances, including emerging synthetic drugs. Portable point-of-care devices and non-invasive testing methods such as saliva and hair analysis have expanded the applicability of drug screening across workplaces, clinical settings, and roadside checks. Automation and cloud-based data management streamline operations, reduce human error, and ensure regulatory compliance, which is particularly important for large-scale testing programs. Market Challenges • Regulatory and Legal Complexities: The global drug screening market faces challenges due to diverse and complex regulatory frameworks across countries and regions. Privacy laws, data protection requirements, and employment regulations impose strict controls on sample collection, testing procedures, reporting, and storage of results. Differences in legal requirements, consent rules, and workplace testing protocols make it difficult for multinational companies to implement standardized drug screening programs. Organizations must navigate these regulations carefully to avoid legal risks, which can increase operational costs and slow market adoption. • Emergence of New Psychoactive Substances: A significant challenge for the market is the continuous appearance of new synthetic and designer drugs that evade traditional detection methods. Laboratories and testing providers must constantly update testing protocols, analytical methods, and confirmatory assays to detect these evolving substances. This requires high investment in research and development, staff training, and technology upgrades, which can increase operational costs and reduce profitability for smaller players. The rapid introduction of novel drugs also makes it difficult to maintain comprehensive testing panels, posing a challenge for regulatory compliance and accurate detection. Market Trends • Adoption of Non-Invasive Testing: One key trend in the global drug screening market is the growing preference for point-of-care and non-invasive testing methods, such as saliva, oral fluid, hair, and sweat tests. These methods are easy to administer, provide rapid results, and reduce discomfort for the donor compared to traditional urine or blood samples. They are increasingly used in workplaces, healthcare facilities, law enforcement, and roadside screening programs, enabling faster decision-making and more widespread testing. • Digital Integration: Another emerging trend is the integration of digital solutions, AI, and cloud-based analytics into drug screening workflows. AI algorithms assist in interpreting complex datasets, detecting low-level substances, and minimizing human error. Digital platforms enhance chain-of-custody management, secure reporting, and regulatory compliance, allowing laboratories, hospitals, and employers to maintain accurate records and track trends in substance use over time.
Drug Screening Segmentation
| By Product and Service | Consumables | |
| Analytical Instruments | ||
| Rapid Testing Devices | ||
| Drug Screening Service | ||
| By Sample Type | Urine Samples | |
| Breath Samples | ||
| Hair Samples | ||
| Oral Fluid Samples | ||
| Other Samples | ||
| By End User | Drug Testing Laboratories | |
| Hospitals & Clinics | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Russia | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| South America | Brazil | |
| Argentina | ||
| Colombia | ||
| MEA | United Arab Emirates | |
| Saudi Arabia | ||
| South Africa | ||
Drug testing laboratories are the largest and fastest-growing segment in the global drug screening market because they provide specialized and regulatory-compliant testing services that cater to forensic applications worldwide. Laboratories are equipped with advanced analytical instruments such as liquid chromatography, gas chromatography, mass spectrometry, and high-sensitivity immunoassays, which allow them to detect a wide range of substances including prescription medications, illicit drugs, and emerging synthetic compounds with high precision. This capability is particularly important for clinical diagnostics, workplace safety programs, and forensic investigations where accuracy and adherence to regulatory standards are critical. The increasing prevalence of substance abuse globally has heightened the demand for professional laboratory services that can manage large volumes of samples efficiently while maintaining quality control and ensuring compliance with international guidelines. Laboratories also provide value-added services such as multi-panel screening, confirmatory testing, digital reporting, and chain-of-custody management, which make them essential for employers, healthcare providers, rehabilitation centers, and legal authorities. Outsourcing testing to laboratories reduces the operational burden on organizations that would otherwise need to maintain their own equipment, trained personnel, and accreditation processes. The scalability and flexibility offered by laboratory services allow clients to adjust testing volumes according to demand, which is especially beneficial for multinational companies, government agencies, and healthcare institutions managing large populations. Technological advancements such as automation, artificial intelligence, and cloud-based data management have further enhanced laboratory capabilities by improving result accuracy, accelerating turnaround times, and ensuring secure storage and reporting of sensitive information. Laboratories also have the capacity to handle diverse sample types including urine, hair, saliva, and blood, which expands their applicability across different testing scenarios and industries. Urine samples are the largest sample type in the global drug screening market because they are cost-effective, easy to collect and are widely accepted across workplace and forensic applications. Urine is a preferred sample type for workplace testing programs, clinical diagnostics, rehabilitation monitoring, and forensic investigations because it offers a relatively wide detection window for commonly abused substances such as opioids, cannabinoids, amphetamines, cocaine, and prescription medications. Collection of urine is non-invasive, straightforward, and does not require specialized equipment, making it highly convenient for large-scale testing programs, particularly in corporate, transportation, and healthcare settings where rapid and repeated testing may be necessary. Cost-effectiveness is another significant advantage, as urine-based testing generally requires lower investment in collection materials, storage, and analytical processing compared to blood or hair samples, allowing organizations to perform frequent testing without incurring high operational costs. The reliability of urine testing has been validated through decades of standardized laboratory methods and immunoassay techniques, which ensures consistency and compliance with global regulatory requirements for both screening and confirmatory tests. Urine samples are also highly adaptable to multi-panel testing, enabling laboratories and service providers to simultaneously detect multiple substances in a single sample, thereby enhancing efficiency and cost-effectiveness for employers, healthcare providers, and forensic agencies. The combination of established testing protocols, availability of rapid immunoassay kits, and compatibility with advanced laboratory instrumentation such as liquid chromatography and mass spectrometry further strengthens the position of urine as the dominant sample type. Drug testing laboratories are the largest end-user segment in the global drug screening market because they provide specialized and legally compliant testing services that are essential for forensic applications worldwide. Laboratories are equipped with advanced analytical instruments such as liquid chromatography, gas chromatography, mass spectrometry, and high-sensitivity immunoassays, which allow them to detect a wide range of substances including prescription drugs, illicit drugs, and emerging synthetic compounds with high accuracy and precision. This capability is critical for clinical diagnostics, workplace safety programs, forensic investigations, and rehabilitation monitoring where results must be legally defensible and compliant with international regulations. The increasing prevalence of substance abuse worldwide has heightened the need for professional laboratory services that can process large sample volumes efficiently while maintaining quality control and regulatory adherence. Laboratories provide additional value-added services such as multi-panel testing, confirmatory analysis, chain-of-custody management, and digital reporting, which are essential for employers, healthcare providers, legal authorities, and government agencies. Outsourcing testing to laboratories also reduces the operational burden on organizations, eliminating the need for investment in costly equipment, specialized personnel training, and accreditation procedures, while ensuring consistent and reliable results. Laboratories are capable of handling diverse sample types including urine, hair, saliva, and blood, which increases their applicability across multiple industries and testing scenarios. Furthermore, technological advancements such as automation, artificial intelligence, and cloud-based data management have improved the efficiency, speed, and traceability of laboratory testing, enabling real-time reporting and minimizing human error. Regulatory compliance is another major factor driving the dominance of laboratories, as many countries mandate accredited facilities for confirmatory and legally defensible testing, creating a high barrier to entry for other service providers or in-house testing models.
to Download this information in a PDF
Drug Screening Market Regional Insights
North America is the largest region in the global drug screening market because of its stringent regulatory frameworks, advanced healthcare infrastructure, widespread workplace testing policies, and early adoption of innovative drug screening technologies. The region, particularly the United States and Canada, has some of the most stringent regulations governing drug testing, including federal workplace safety laws, healthcare compliance standards, and law enforcement protocols that require accurate and legally defensible results. Agencies such as the Department of Transportation, Occupational Safety and Health Administration, and state-level health authorities mandate pre-employment, random, and post-incident testing in safety-sensitive industries including transportation, energy, healthcare, and aviation, which ensures consistent demand for drug screening products and services. North America also experiences a significant burden from substance abuse including opioids, cannabinoids, stimulants, and prescription medications, creating a strong public health focus on early detection and intervention through comprehensive testing programs. The advanced healthcare infrastructure in the region, including state-of-the-art laboratories, hospitals, and clinics, supports high-throughput, accurate testing capabilities that integrate with electronic health records and digital reporting platforms to maintain compliance and traceability. Additionally, North America is a leader in research and development of innovative drug screening technologies such as multi-panel immunoassays, mass spectrometry, chromatography techniques, and AI-enabled analytics, which further strengthens the adoption of advanced solutions across clinical and workplace environments. Employers across multiple industries implement mandatory drug testing as part of occupational safety programs and employee wellness initiatives, while government-funded programs and public awareness campaigns support widespread clinical and forensic screening.
to Download this information in a PDF
Key Development
• April 2025: Test Your Poison unveiled a novel line of drug testing kits designed for detection of hazardous impurities in MDMA, cocaine, and heroin. These purity kits are integral in mitigating the risk of overdose and toxic contamination, especially with the increasing rates of drug-related incidents. This product launch marked a preventive measure to address the growing overdose crisis by prioritizing safety, education, and accessibility within the risk areas. • January 2025: Intelligent Bio Solutions Inc. (INBS) partnered with the UK-based construction firm Princebuild to implement its Intelligent Fingerprinting Drug Screening System. The fingerprint-based solution will replace saliva-based methods and will be implemented at Princebuild’s seven UK locations. This innovative approach enhances workplace safety and regulatory compliance while swiftly and hygienically protecting employee privacy during the drug screening process. • January 2025: Northlane Capital Partners (NCP) announced an investment in United States Drug Testing Laboratories Inc. (USDTL), a forensic toxicology laboratory specializing in alcohol and substance use testing. This partnership was formed alongside USDTL's management team and founders, Veronica and Doug Lewis. The investment aims to support USDTL's continued expansion and enhance its specialized testing capabilities. • March 2024: BioXcelerate, a pioneering health data science segment of Optima Partners Limited, unveiled a revolutionary AI tool designed to speed up the identification and development of new pharmaceuticals. The instrument, referred to as PleioGraph, can evaluate intricate medical data 100 times quicker than current leading techniques utilized to uncover biological networks that clarify disease risk and guide drug discovery. • February 2024: Veriteque USA partnered with OraSure Technologies under a new distribution agreement. This collaboration enables OraSure to include Veriteque's SwabTek surface test kits in its lineup of oral fluid drug screening products. SwabTek offers single-use, dry reagent tests for narcotics and explosives, designed for use at home, in educational settings, and workplaces. • January 2024: The Loop announced the offering of a regular drug testing service, the first service in UK that started operating in Bristol, representing a significant shift in national drug policy. This service enabled chronic users of heroin, crack, benzodiazepines, and spice to access testing that aimed to identify harmful cutting or adulterating agents such as high-strength synthetic opioids, nitrazines, and fentanyl. • December 2023: Quest Diagnostics introduced its new confirmatory testing service for new psychoactive substances (NPS). The updated panel, which checks for 88 substances, encompasses a wide range of drug categories, including designer opioids, designer benzodiazepines, designer stimulants, fentanyl derivatives, synthetic cannabinoids, and various illicit additives.
Companies Mentioned
- Abbott Laboratories
- Drägerwerk AG & Co. KGaA
- Siemens Healthineers
- Shimadzu Corporation
- OraSure Technologies
- Quest Diagnostics
- Lifeloc Technologies, Inc
- Bio-Rad Laboratories, Inc.
- Psychemedics Corporation
- Agilent Technologies, Inc.
- Thermo Fisher Scientific Inc
- Roche Holding AG
- Labcorp Holdings Inc.
- Alfa Scientific Designs, Inc.
- Premier Biotech, Inc.
Table of Contents
- 1. Executive Summary
- 2. Market Dynamics
- 2.1. Market Drivers & Opportunities
- 2.2. Market Restraints & Challenges
- 2.3. Market Trends
- 2.4. Supply chain Analysis
- 2.5. Policy & Regulatory Framework
- 2.6. Industry Experts Views
- 3. Research Methodology
- 3.1. Secondary Research
- 3.2. Primary Data Collection
- 3.3. Market Formation & Validation
- 3.4. Report Writing, Quality Check & Delivery
- 4. Market Structure
- 4.1. Market Considerate
- 4.2. Assumptions
- 4.3. Limitations
- 4.4. Abbreviations
- 4.5. Sources
- 4.6. Definitions
- 5. Economic /Demographic Snapshot
- 6. Global Drug Screening Market Outlook
- 6.1. Market Size By Value
- 6.2. Market Share By Region
- 6.3. Market Size and Forecast, By Geography
- 6.4. Market Size and Forecast, By Product and Service
- 6.5. Market Size and Forecast, By Sample Type
- 6.6. Market Size and Forecast, By End User
- 7. North America Drug Screening Market Outlook
- 7.1. Market Size By Value
- 7.2. Market Share By Country
- 7.3. Market Size and Forecast, By Product and Service
- 7.4. Market Size and Forecast, By Sample Type
- 7.5. Market Size and Forecast, By End User
- 7.6. United States Drug Screening Market Outlook
- 7.6.1. Market Size by Value
- 7.6.2. Market Size and Forecast By Product and Service
- 7.6.3. Market Size and Forecast By Sample Type
- 7.6.4. Market Size and Forecast By End User
- 7.7. Canada Drug Screening Market Outlook
- 7.7.1. Market Size by Value
- 7.7.2. Market Size and Forecast By Product and Service
- 7.7.3. Market Size and Forecast By Sample Type
- 7.7.4. Market Size and Forecast By End User
- 7.8. Mexico Drug Screening Market Outlook
- 7.8.1. Market Size by Value
- 7.8.2. Market Size and Forecast By Product and Service
- 7.8.3. Market Size and Forecast By Sample Type
- 7.8.4. Market Size and Forecast By End User
- 8. Europe Drug Screening Market Outlook
- 8.1. Market Size By Value
- 8.2. Market Share By Country
- 8.3. Market Size and Forecast, By Product and Service
- 8.4. Market Size and Forecast, By Sample Type
- 8.5. Market Size and Forecast, By End User
- 8.6. Germany Drug Screening Market Outlook
- 8.6.1. Market Size by Value
- 8.6.2. Market Size and Forecast By Product and Service
- 8.6.3. Market Size and Forecast By Sample Type
- 8.6.4. Market Size and Forecast By End User
- 8.7. United Kingdom (UK) Drug Screening Market Outlook
- 8.7.1. Market Size by Value
- 8.7.2. Market Size and Forecast By Product and Service
- 8.7.3. Market Size and Forecast By Sample Type
- 8.7.4. Market Size and Forecast By End User
- 8.8. France Drug Screening Market Outlook
- 8.8.1. Market Size by Value
- 8.8.2. Market Size and Forecast By Product and Service
- 8.8.3. Market Size and Forecast By Sample Type
- 8.8.4. Market Size and Forecast By End User
- 8.9. Italy Drug Screening Market Outlook
- 8.9.1. Market Size by Value
- 8.9.2. Market Size and Forecast By Product and Service
- 8.9.3. Market Size and Forecast By Sample Type
- 8.9.4. Market Size and Forecast By End User
- 8.10. Spain Drug Screening Market Outlook
- 8.10.1. Market Size by Value
- 8.10.2. Market Size and Forecast By Product and Service
- 8.10.3. Market Size and Forecast By Sample Type
- 8.10.4. Market Size and Forecast By End User
- 8.11. Russia Drug Screening Market Outlook
- 8.11.1. Market Size by Value
- 8.11.2. Market Size and Forecast By Product and Service
- 8.11.3. Market Size and Forecast By Sample Type
- 8.11.4. Market Size and Forecast By End User
- 9. Asia-Pacific Drug Screening Market Outlook
- 9.1. Market Size By Value
- 9.2. Market Share By Country
- 9.3. Market Size and Forecast, By Product and Service
- 9.4. Market Size and Forecast, By Sample Type
- 9.5. Market Size and Forecast, By End User
- 9.6. China Drug Screening Market Outlook
- 9.6.1. Market Size by Value
- 9.6.2. Market Size and Forecast By Product and Service
- 9.6.3. Market Size and Forecast By Sample Type
- 9.6.4. Market Size and Forecast By End User
- 9.7. Japan Drug Screening Market Outlook
- 9.7.1. Market Size by Value
- 9.7.2. Market Size and Forecast By Product and Service
- 9.7.3. Market Size and Forecast By Sample Type
- 9.7.4. Market Size and Forecast By End User
- 9.8. India Drug Screening Market Outlook
- 9.8.1. Market Size by Value
- 9.8.2. Market Size and Forecast By Product and Service
- 9.8.3. Market Size and Forecast By Sample Type
- 9.8.4. Market Size and Forecast By End User
- 9.9. Australia Drug Screening Market Outlook
- 9.9.1. Market Size by Value
- 9.9.2. Market Size and Forecast By Product and Service
- 9.9.3. Market Size and Forecast By Sample Type
- 9.9.4. Market Size and Forecast By End User
- 9.10. South Korea Drug Screening Market Outlook
- 9.10.1. Market Size by Value
- 9.10.2. Market Size and Forecast By Product and Service
- 9.10.3. Market Size and Forecast By Sample Type
- 9.10.4. Market Size and Forecast By End User
- 10. South America Drug Screening Market Outlook
- 10.1. Market Size By Value
- 10.2. Market Share By Country
- 10.3. Market Size and Forecast, By Product and Service
- 10.4. Market Size and Forecast, By Sample Type
- 10.5. Market Size and Forecast, By End User
- 10.6. Brazil Drug Screening Market Outlook
- 10.6.1. Market Size by Value
- 10.6.2. Market Size and Forecast By Product and Service
- 10.6.3. Market Size and Forecast By Sample Type
- 10.6.4. Market Size and Forecast By End User
- 10.7. Argentina Drug Screening Market Outlook
- 10.7.1. Market Size by Value
- 10.7.2. Market Size and Forecast By Product and Service
- 10.7.3. Market Size and Forecast By Sample Type
- 10.7.4. Market Size and Forecast By End User
- 10.8. Colombia Drug Screening Market Outlook
- 10.8.1. Market Size by Value
- 10.8.2. Market Size and Forecast By Product and Service
- 10.8.3. Market Size and Forecast By Sample Type
- 10.8.4. Market Size and Forecast By End User
- 11. Middle East & Africa Drug Screening Market Outlook
- 11.1. Market Size By Value
- 11.2. Market Share By Country
- 11.3. Market Size and Forecast, By Product and Service
- 11.4. Market Size and Forecast, By Sample Type
- 11.5. Market Size and Forecast, By End User
- 11.6. United Arab Emirates (UAE) Drug Screening Market Outlook
- 11.6.1. Market Size by Value
- 11.6.2. Market Size and Forecast By Product and Service
- 11.6.3. Market Size and Forecast By Sample Type
- 11.6.4. Market Size and Forecast By End User
- 11.7. Saudi Arabia Drug Screening Market Outlook
- 11.7.1. Market Size by Value
- 11.7.2. Market Size and Forecast By Product and Service
- 11.7.3. Market Size and Forecast By Sample Type
- 11.7.4. Market Size and Forecast By End User
- 11.8. South Africa Drug Screening Market Outlook
- 11.8.1. Market Size by Value
- 11.8.2. Market Size and Forecast By Product and Service
- 11.8.3. Market Size and Forecast By Sample Type
- 11.8.4. Market Size and Forecast By End User
- 12. Competitive Landscape
- 12.1. Competitive Dashboard
- 12.2. Business Strategies Adopted by Key Players
- 12.3. Key Players Market Share Insights and Analysis, 2025
- 12.4. Key Players Market Positioning Matrix
- 12.5. Porter's Five Forces
- 12.6. Company Profile
- 12.6.1. Abbott Laboratories
- 12.6.1.1. Company Snapshot
- 12.6.1.2. Company Overview
- 12.6.1.3. Financial Highlights
- 12.6.1.4. Geographic Insights
- 12.6.1.5. Business Segment & Performance
- 12.6.1.6. Product Portfolio
- 12.6.1.7. Key Executives
- 12.6.1.8. Strategic Moves & Developments
- 12.6.2. Agilent Technologies, Inc.
- 12.6.3. Thermo Fisher Scientific Inc
- 12.6.4. Bio-Rad Laboratories, Inc.
- 12.6.5. Roche Holding AG
- 12.6.6. Shimadzu Corporation
- 12.6.7. Drägerwerk AG & Co. KGaA
- 12.6.8. Siemens Healthineers AG
- 12.6.9. Quest Diagnostics Incorporated
- 12.6.10. OraSure Technologies, Inc.
- 12.6.11. Premier Biotech, Inc.
- 12.6.12. Alfa Scientific Designs, Inc.
- 12.6.13. Lifeloc Technologies, Inc
- 12.6.14. Psychemedics Corporation
- 12.6.15. Labcorp Holdings Inc.
- 12.6.16. Omega Laboratories, Inc.
- 13. Strategic Recommendations
- 14. Annexure
- 14.1. FAQ`s
- 14.2. Notes
- 15. Disclaimer
Table 2: Influencing Factors for Drug Screening Market, 2025
Table 3: Top 10 Counties Economic Snapshot 2024
Table 4: Economic Snapshot of Other Prominent Countries 2022
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Global Drug Screening Market Size and Forecast, By Geography (2020 to 2031F) (In USD Billion)
Table 7: Global Drug Screening Market Size and Forecast, By Product and Service (2020 to 2031F) (In USD Billion)
Table 8: Global Drug Screening Market Size and Forecast, By Sample Type (2020 to 2031F) (In USD Billion)
Table 9: Global Drug Screening Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 10: North America Drug Screening Market Size and Forecast, By Product and Service (2020 to 2031F) (In USD Billion)
Table 11: North America Drug Screening Market Size and Forecast, By Sample Type (2020 to 2031F) (In USD Billion)
Table 12: North America Drug Screening Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 13: United States Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 14: United States Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 15: United States Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 16: Canada Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 17: Canada Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 18: Canada Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 19: Mexico Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 20: Mexico Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 21: Mexico Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 22: Europe Drug Screening Market Size and Forecast, By Product and Service (2020 to 2031F) (In USD Billion)
Table 23: Europe Drug Screening Market Size and Forecast, By Sample Type (2020 to 2031F) (In USD Billion)
Table 24: Europe Drug Screening Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 25: Germany Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 26: Germany Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 27: Germany Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 28: United Kingdom (UK) Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 29: United Kingdom (UK) Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 30: United Kingdom (UK) Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 31: France Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 32: France Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 33: France Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 34: Italy Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 35: Italy Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 36: Italy Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 37: Spain Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 38: Spain Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 39: Spain Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 40: Russia Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 41: Russia Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 42: Russia Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 43: Asia-Pacific Drug Screening Market Size and Forecast, By Product and Service (2020 to 2031F) (In USD Billion)
Table 44: Asia-Pacific Drug Screening Market Size and Forecast, By Sample Type (2020 to 2031F) (In USD Billion)
Table 45: Asia-Pacific Drug Screening Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 46: China Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 47: China Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 48: China Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 49: Japan Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 50: Japan Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 51: Japan Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 52: India Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 53: India Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 54: India Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 55: Australia Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 56: Australia Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 57: Australia Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 58: South Korea Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 59: South Korea Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 60: South Korea Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 61: South America Drug Screening Market Size and Forecast, By Product and Service (2020 to 2031F) (In USD Billion)
Table 62: South America Drug Screening Market Size and Forecast, By Sample Type (2020 to 2031F) (In USD Billion)
Table 63: South America Drug Screening Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 64: Brazil Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 65: Brazil Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 66: Brazil Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 67: Argentina Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 68: Argentina Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 69: Argentina Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 70: Colombia Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 71: Colombia Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 72: Colombia Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 73: Middle East & Africa Drug Screening Market Size and Forecast, By Product and Service (2020 to 2031F) (In USD Billion)
Table 74: Middle East & Africa Drug Screening Market Size and Forecast, By Sample Type (2020 to 2031F) (In USD Billion)
Table 75: Middle East & Africa Drug Screening Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 76: United Arab Emirates (UAE) Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 77: United Arab Emirates (UAE) Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 78: United Arab Emirates (UAE) Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 79: Saudi Arabia Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 80: Saudi Arabia Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 81: Saudi Arabia Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 82: South Africa Drug Screening Market Size and Forecast By Product and Service (2020 to 2031F) (In USD Billion)
Table 83: South Africa Drug Screening Market Size and Forecast By Sample Type (2020 to 2031F) (In USD Billion)
Table 84: South Africa Drug Screening Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 85: Competitive Dashboard of top 5 players, 2025
Table 86: Key Players Market Share Insights and Analysis for Drug Screening Market 2025
Figure 2: Market attractiveness Index, By Region 2031F
Figure 3: Market attractiveness Index, By Segment 2031F
Figure 4: Global Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: Global Drug Screening Market Share By Region (2025)
Figure 6: North America Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: North America Drug Screening Market Share By Country (2025)
Figure 8: US Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 9: Canada Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 10: Mexico Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 11: Europe Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 12: Europe Drug Screening Market Share By Country (2025)
Figure 13: Germany Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 14: United Kingdom (UK) Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 15: France Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 16: Italy Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 17: Spain Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 18: Russia Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 19: Asia-Pacific Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 20: Asia-Pacific Drug Screening Market Share By Country (2025)
Figure 21: China Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 22: Japan Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 23: India Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 24: Australia Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 25: South Korea Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 26: South America Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 27: South America Drug Screening Market Share By Country (2025)
Figure 28: Brazil Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 29: Argentina Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 30: Colombia Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 31: Middle East & Africa Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 32: Middle East & Africa Drug Screening Market Share By Country (2025)
Figure 33: United Arab Emirates (UAE) Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 34: Saudi Arabia Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 35: South Africa Drug Screening Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 36: Porter's Five Forces of Global Drug Screening Market
Drug Screening Market Research FAQs
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Trusted Partners
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (16 February, 2026)
- Notify To Team (16 February, 2026)
- Report updation (17 February, 2026)
- Report Quality Check (17 February, 2026)
- Report Dispatch (18 February, 2026)
- Hard Copy
Recently Viewed Products
Global Drug Screening Market Outlook, 2031
We are friendly and approachable, give us a call.